Acetazolamide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Acetazolamide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Report Description
Acetazolamide is an enzyme inhibitor, which acts specifically on carbonic anhydrase. Acetazolamide, sold under the trade name Diamox, is used to treat glaucoma, altitude sickness, epilepsy, fluid retention, heart failure, and seizures.
In addition to this, acetazolamide (carbonic anhydrase inhibitor) is effective in controlling fluid secretions, to treat certain convulsive disorders, and promotes diuresis in instances of abnormal fluid retention such as cardiac edema.
Increasing effectiveness of acetazolamide in treating other indication such as drug induced edema and brain tumor glioblastoma is offering growth prospective for key drug manufacturers in this market. For instance, according to a new study published in Science Translational Medicine Journal in July 2018, acetazolamide may also be effective in treating glioblastoma, fast-growing brain tumor. As per the study findings, acetazolamide can restore temozolomide’s (TMZ) ability to kill tumor cells. Furthermore, the study suggested that the combination of acetazolamide with TMZ may be an effective subgroup to consider for trial for patients with high BCL-3 expression.
Market Dynamics
Increasing prevalence of glaucoma and its risk factors among global population is propelling demand for acetazolamide during the forecast period. Moreover, acetazolamide is commonly used for preventing high altitude illness, this increases the utility of the drug.
For instance, according to the International Journal of Advanced Medical and Health Research, 2015, glaucoma is seen to be the second major reason causing blindness among people across the world, followed by cataract.
Furthermore, according to the BrightFocus Foundation, June 2021 data findings, over 3 million Americans suffer from glaucoma, out of which 2.7 million (aged 40 and older) are affected by its most common form, open-angle glaucoma. Also, high prevalence of eye disorder in the geriatric population and nutritional deficiency in the younger population due to changing food habits are other factors affecting the health of the people globally, which might lead to boost growth of acetazolamide market. Acetazolamide capsule taken once a day by patients with chronic glaucoma offers a substantial pressure-lowering effect, which lasts at least 23 hours.
Acetazolamide helps in preventing acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone, which can mask symptoms and therefore carries greater risk.
Key features of the study:
This report provides in-depth analysis of acetazolamide market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, drug approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global acetazolamide market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as part of this study include Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd., Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc., Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future drug launch, manufacturing up-gradation, market expansion, and marketing tactics
The global acetazolamide market report caters to various stakeholders in this industry including investors, suppliers, acetazolamide based product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acetazolamide market.
Detailed Segmentation:
Global Acetazolamide Market, By Formulation:
Tablets
Capsules
Injection
Global Acetazolamide Market, By Application:
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
Global Acetazolamide Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Acetazolamide Market, By Geography:
North America
By Country:
U.S.
Canada
By Formulation:
Tablets
Capsules
Injection
By Application
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Europe
By Country:
Germany
France
Italy
UK
Spain
Russia
Rest of Europe
By Formulation:
Tablets
Capsules
Injection
By Application
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Asia Pacific
By Country:
China
India
Japan
South Korea
Australia
Rest of Asia Pacific
By Formulation:
Tablets
Capsules
Injection
By Application
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Formulation:
Tablets
Capsules
Injection
By Application
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Latin America
By Country:
Brazil
Argentina
Mexico
Rest of Latin America
By Formulation:
Tablets
Capsules
Injection
By Application
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Africa
By Country:
South Africa
Central Africa
North Africa
By Formulation:
Tablets
Capsules
Injection
By Application
Glaucoma
Epilepsy
Drug-induced Edema
Altitude Sickness
Fluid Retention
Heart Failure
Seizures
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Performance
Recent Developments
Strategies
Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
Heritage Pharmaceuticals Inc.
Nostrum Laboratories Inc.
Novast Laboratories Ltd.
Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.)
Lannett Company, Inc.
Strides Shasun Limited
X-GEN Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.